ArticleCancer medicine2019
Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- A Case of Primary Cutaneous BRAFThe Australasian journal of dermatology · 2026Article
- Blastic plasmacytoid dendritic cell neoplasm following Langerhans cell histiocytosis.JAAD case reports · 2026Article
- Langerhans Cell Histiocytosis Associated With Chronic Myeloid Leukemia: A Pediatric Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Tumoral Stage of Mycosis Fungoides, Misdiagnosed With Wells Syndrome and Langerhans Cell Histiocytosis Histologically: A Challenging Case and Review of the Literature.Cancer reports (Hoboken, N.J.) · 2025Review
- Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder.The Journal of clinical endocrinology and metabolism · 2025Review
- Advances in allogeneic hematopoietic stem cell transplantation for Langerhans cell histiocytosis in children.Frontiers in immunology · 2025Review
- Pulmonary Langerhans cell histiocytosis with multiple cavitary nodules after lung cancer surgery.Respirology case reports · 2024Article
- Long-term outcomes among adults with Langerhans cell histiocytosis.Blood advances · 2023Article
- Article
- Clinical and prognostic features of Langerhans cell histiocytosis in adults.Cancer science · 2023Article
- A Case of a Coexisting Carcinosarcoma Ex Pleomorphic Adenoma With Langerhans Cell Histiocytosis in the Parotid Gland.Cureus · 2023Article
- Incidental Langerhans cell histiocytosis associated with metastatic neuroendocrine tumor in the adult liver.Clinical case reports · 2023Article
- Molecular and oral manifestations of langerhans cell histiocytosis preceding acute myeloid leukemia.BMC oral health · 2022Article
- Experiences of a Single Center in One Hundred Ninety-Four Adult Patients With Langerhans Cell Histiocytosis.Journal of hematology · 2022Article
- Article
- NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.Biology · 2021Article
- Concomitant Langerhans cell histiocytosis of cervical lymph nodes in adult patients with papillary thyroid carcinoma: A report of two cases and review of the literature.Autopsy & case reports · 2021Article
- Case Report: Opposite Effects ofFrontiers in oncology · 2021Article
- Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.The journal of pathology. Clinical research · 2021Article
- Update on Pulmonary Langerhans Cell Histiocytosis.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundLangerhans cell histiocytosis (LCH) is a rare disorder of histiocyte proliferation. Previous case studies suggest a higher prevalence of hematologic and solid malignancies among LCH patients, possibly due to treatment with tumorigenic agents such as etoposide. We report the first large, single-institution experience of adult LCH patients with additional malignancies to study the characteristics of these patients.
methodsWe identified 132 consecutive patients >18 years of age with histologically confirmed LCH at our center between 1990 and 2015. Demographics and detailed oncologic history were recorded to identify patients with additional malignancies.
resultsOf 132 adult LCH patients, 42 (32%) patients had an additional malignancy. There were 53 malignancies among the 42 patients, with 31 (58%) preceding LCH diagnosis, 11 concurrent (≤3 months; 21%) with LCH diagnosis, and 11 (21%) after. Median age was 54 years (range 28-89) with a median follow-up of 3.7 years (0.1-22.2) for this cohort. OS at 3 years was 98% in patients with LCH alone and 82% among patients with additional malignancies, with 30 (71%) alive at last follow-up. Solid tumors, lymphomas, and other hematologic malignancies were observed as follows: 39 (74%), 9 (17%), and 5 (9%).
conclusionOur cohort of adult LCH patients demonstrates an unusually high number of additional malignancies. Our study includes predominantly malignancies diagnosed preceding or concurrent with LCH, suggesting a cause of malignancy independent of LCH treatment. Further exploration of the biology of this rare disease may elucidate the mechanism of frequent additional malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.